VHL Logo

    • Español
    • English
    • Português
    • Français
    Home > > Semaglutide for managing overweight and obesity

    Semaglutide for managing overweight and obesity

    England. National Institute for Health and Care Excellence.
    Publication year: 2023

    Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults. Commercial availability The Wegovy brand of semaglutide is not commercially available yet.
    Insulin/therapeutic use, Obesity Management, Overweight/drug therapy, Exercise, Caloric Restriction
    Fulltext

    Related

    • Terms and conditions of use
    • Privacy Policy
    • WordPress version 4.9.8
    • BVS-Site Plugin version 0.6.0